Hikal hit an upper circuit of 5% at Rs 345 after the company's consolidated net profit surged 108.1% to Rs 50.92 crore in Q4 FY21 as against Rs 24.47 crore in Q4 FY20.
Total revenue from operations increased by 40.5% year-on-year (YoY) to Rs 532.46 crore during the quarter.
On the segmental front, revenue from pharmaceuticals was Rs 297.68 crore (up 31.5% YoY) while that from crop protection business was Rs 234.78 crore (up 53.8% YoY) in the fourth quarter.
Profit before tax in Q4 FY21 was at Rs 80.61 crore, up by 113.7% from Rs 37.72 crore in Q4 FY20.
The company posted 57.7% jump in consolidated net profit to Rs 133.15 crore on 14.1% rise in total revenue from operations to Rs 1,720.44 crore in the year ended 31 March 2021 over the year ended 31 March 2020.
Also Read
The company's board has recommended a final dividend of Rs 1 per share for the financial year 2020-21.
Hikal is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharmaceutical ingredients (APIs) and contract research activities.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
